Evidence map›Paper›PMID 32434589›Full record

ArticleBreast cancer research : BCR2020

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.

Lori J Goldstein, Raymond P Perez, Denise Yardley, Linda K Han, James M Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu and 2 more

Abstract readPublished Erratum
In one paragraph

Article in Breast cancer research : BCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Lori J GoldsteinDepartment of Medical Oncology, The Hospital of Fox Chase Cancer Center, Philadelphia, PA, USA.
Raymond P PerezUniversity of Kansas Medical Research Center, Fairway, KS, USA.
Denise YardleyTennessee Oncology, Nashville, TN, USA.
Linda K HanIndiana University Simon Cancer Center, Indianapolis, IN, USA.
James M ReubenDepartment of Hematopathology-Research, MD Anderson Cancer Center, Houston, TX, USA.
Hui GaoDepartment of Hematopathology-Research, MD Anderson Cancer Center, Houston, TX, USA.
Susan McCannaResearch and Development, Dompé farmaceutici S.p.A., 20122, Milan, Italy.
Beth ButlerResearch and Development, Dompé farmaceutici S.p.A., 20122, Milan, Italy.
Pier Adelchi RuffiniResearch and Development, Dompé farmaceutici S.p.A., 20122, Milan, Italy.
Yi LiuThe Methodist Hospital Research Institute, 6445 Main Street, Houston, TX, 77030, USA.
Roberto R RosatoThe Methodist Hospital Research Institute, 6445 Main Street, Houston, TX, 77030, USA.
Jenny C ChangThe Methodist Hospital Research Institute, 6445 Main Street, Houston, TX, 77030, USA. jcchang@houstonmethodist.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via the original article.

Identifiers

PMID32434589
PMCPMC7238734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.